NOAC in Asian.
10.18501/arrhythmia.2016.004
- Author:
In Geol SONG
1
;
Sung Hwan KIM
Author Information
1. Division of Cardiology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
- Publication Type:Review
- Keywords:
Atrial Fibrillation;
Anticoagulation;
Stroke;
Embolism
- MeSH:
Anticoagulants;
Asian Continental Ancestry Group*;
Atrial Fibrillation;
Body Surface Area;
Diet;
Embolism;
Hemorrhage;
Humans;
Polymorphism, Genetic;
Stroke;
Vitamin K
- From:International Journal of Arrhythmia
2016;17(1):32-35
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Anticoagulation treatment, including novel or non-vitamin K-dependent antagonist oral anticoagulants (NOACs), is essential to prevent thromboembolic events in high-risk atrial fibrillation patients. There are not enough studies on the effect and safety of NOACs in Asians. Due to the low body surface area, genetic polymorphism, and herbal diet of Asians, it is difficult to attain optimal anticoagulation with traditional anticoagulation treatment using vitamin K antagonists, and more bleeding complications are reported with this treatment. In several recent studies, the use of NOACs in Asians resulted in lower thrombo- embolic events and fewer bleeding complications than those with a vitamin K antagonist. Given the race-related differences of Asians, NOACs have sufficient efficacy and safety for the prevention of thromboembolic events in patients with atrial fibrillation.
